Exhibit 10.2





 


EXECUTION COPY


 


CAPITAL ACCESS AGREEMENT


 


This CAPITAL ACCESS
AGREEMENT (the “Agreement”), is dated as of June 10, 2016, by and between Immune Pharmaceuticals
Inc., a Delaware corporation, (the “Company”), and Regatta Select Healthcare, LLC, a Delaware limited
liability company (including any designee(s) thereof, the “Investor”).


 


WHEREAS:


 


Subject to the terms and conditions set
forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to 3,700,000
shares of the Company's common stock, $0.0001 par value (the “Common Stock”). The shares of Common Stock to
be purchased hereunder are referred to herein as the “Purchase Shares.”


 


NOW THEREFORE, in consideration
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Company and the Investor hereby agree as follows:


 


		1.	CERTAIN DEFINITIONS.



 


For purposes of this
Agreement, the following terms shall have the following meanings:


 


“ADV”
means the average daily volume of the shares traded on the Principal Market computed using the 10 Business Days prior to the Put
Date.


 


“Available
Shares” means initially 3,700,000 Purchased Shares, which amount shall be reduced by the Purchased Shares each time the
Investor purchases such shares of Common Stock pursuant to Section 2 hereof.


 


“Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.


 


“Base Prospectus”
means the Company’s final base prospectus, dated October 3, 2014, a form of which is included in the Registration Statement,
including the documents incorporated by reference therein.


 


“Business
Day” means any day on which the Principal Market is open for trading, including any day on which the Principal Market
is open for trading for a period of time less than the customary time.


 


“Closing Market
Price” means, for any security as of any date, the last closing market price for such security on the Principal Market
as reported by the Principal Market.


 


“Commitment
Amount” means up to 3,700,000 shares of the Company’s Common Stock or $2.2 million over the course of no more than
12 months (the “Commitment Period”).


 


“Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
which is designated as “Confidential,” “Proprietary” or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information
within ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed to
a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly
known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly
known and made generally available after disclosure by the disclosing party to the receiving party through no action or inaction
of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the disclosing party
as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained by the
receiving party from a third party without a breach of such third party’s obligations of confidentiality; (v) is independently
developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as shown
by documents and other competent evidence in the receiving party’s possession; or (vi) is required by law, including federal
securities laws and the rules and regulations of the Principal Market, to be disclosed by the receiving party, provided that the
receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in
obtaining an order protecting the information from public disclosure.


 


“Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.


 


“DTC”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.


 




     


     


    

 


“DWAC Shares”
means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction
on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified Deposit/Withdrawal
at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar program hereafter
adopted by DTC performing substantially the same function.


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Floor Price”
means 75% of the average closing bid price for the Common Stock for the 10 Business Days prior to the Put Date, which Floor Price
shall be appropriately adjusted for any reorganization, recapitalization, stock dividend, stock split or other similar transaction
and, effective upon the consummation of any such reorganization, recapitalization, stock dividend, stock split or other similar
transaction, the Floor Price shall mean the adjusted price.


 


“Initial Prospectus
Supplement” means the prospectus supplement to the Base Prospectus complying with Rule 424(b) under the Securities Act
that is filed with the SEC and delivered by the Company to the Investor upon the execution and delivery of this Agreement in accordance
with Section 5(a), including the documents incorporated by reference therein.


 


“Market Price”
means the lowest price of the Common Stock during the Pricing Period.


 


“Material
Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the
results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than
any material adverse effect that resulted exclusively from (A) any change in the United States or foreign economies or securities
or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole,
(B) any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a
disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
acts of war, sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor,
its affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement, (E) the
effect of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its
Subsidiaries, taken as a whole, or (F) any change resulting from compliance with terms of this Agreement or the consummation
of the transactions contemplated by this Agreement, or (iii) the Company’s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document to be performed as of the date of determination.


 


“Maturity
Date” means the first day of the month immediately following the twelve (12) month anniversary of the Commencement Date.


 


“Person”
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.


 


“Pricing Period”
means the five (5) consecutive Business Days immediately after the Put Date.


 


“Principal
Market” means The NASDAQ Capital Market; provided however, that in the event the Company’s Common Stock is ever
listed or traded on The NASDAQ Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE MKT, LLC,
the OTC Bulletin Board, the OTCQB, or the OTCQX (or any successors to any of the foregoing), then the “Principal Market”
shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.


 


“Prospectus”
means the Base Prospectus, as supplemented by any Prospectus Supplement (including the Initial Prospectus Supplement), including
the documents incorporated by reference therein.


 


“Prospectus
Supplement” means any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed
with the SEC pursuant to Rule 424(b) under the Securities Act in connection with the transactions contemplated by this Agreement,
including the documents incorporated by reference therein.


 


“Purchase
Amount” means, with respect to any Purchase made hereunder, the dollar value of any Purchase made hereunder.


 


“Purchase
Price” means, with respect to any Purchase made pursuant to Section 2(a) hereof, eighty-three percent (83%) of the Market
Price.


 


“Put Ceiling”
means the lesser of (a) $250,000 in Purchase Shares or (b) 200% of the ADV multiplied by the average of the daily closing prices
for the ten (10) Business Days immediately preceding the Put Date.


 


“Put Closing
Date” means, with respect to any Purchase made pursuant to Section 2(a) hereof, five (5) business days after the Put
Date.


 




    	 	- 2 -	 



     


    

  


“Put Date”
means the date of delivery of the Put Notice.


 


“Put Notice”
means, with respect to any Purchase pursuant to Section 2(a) hereof, an irrevocable written notice from the Company to the Investor
directing the Investor to buy such applicable amount of Purchase Shares at the applicable Purchase Price as specified by the Company
therein on the Put Closing Date.


 


“Registration
Statement” means the effective registration statement on Form S-3 (Commission File No. 333- 198647) filed by the
Company with the SEC pursuant to the Securities Act for the registration of shares of its Common Stock, and certain other securities,
as such Registration Statement has been or may be amended and supplemented from time to time, including all documents filed as
part thereof or incorporated by reference therein, and including all information deemed to be a part thereof at the time of effectiveness
pursuant to Rule 430B of the Securities Act, including any comparable successor registration statement filed by the Company with
the SEC pursuant to the Securities Act for the registration of shares of its Common Stock, including the Purchase Shares.


 


“SEC”
means the U.S. Securities and Exchange Commission.


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


“Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting
stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated
under the Securities Act.


 


“Term”
means that period commencing with the Commencement Date and ending on the earlier of (a) the drawing down of the entire Commitment
Amount or (b) the date that shall be 12 months after the Commencement Date.


 


“Transaction
Documents” means, collectively, this Agreement and the schedules and exhibits hereto, and each of the other agreements,
documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated
hereby and thereby.


 


“Transfer
Agent” means VStock Transfer, LLC, or such other Person who is then serving as the transfer agent for the Company in
respect of the Common Stock.


 


		2.	PURCHASE OF COMMON STOCK.



 


Subject to the terms
and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has the obligation
to purchase from the Company, Purchase Shares as follows:


 


(a)  Commencement
of Regular Sales of Common Stock. Upon the satisfaction of the conditions set forth in Sections 7 and 8 hereof (the “Commencement”
and the date of satisfaction of such conditions the “Commencement Date”), the Investor shall during the Term
purchase up to 3,700,000 Purchase Shares at the Purchase Price. Beginning one (1) Business Day following the Commencement Date,
the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a Put Notice
from time to time, to purchase any number of Purchase Shares (each such purchase a “Purchase”), at the Purchase
Price on the Put Date, subject to the Put Ceiling. If the Company delivers any Put Notice for a number of Purchase Shares in excess
of the limitations contained in the immediately preceding sentence, such Put Notice shall be void ab initio to the extent
of the amount by which the number of Purchase Shares set forth in such Put Notice exceeds the number of Purchase Shares which the
Company is permitted to include in such Purchase Notice in accordance herewith, and the Investor shall have no obligation to purchase
such excess Purchase Shares in respect of such Put Notice; provided that the Investor shall remain obligated to purchase the number
of Purchase Shares which the Company is permitted to include in such Put Notice. The Company shall be permitted to deliver up to
four (4) Put Notices per month. For the first put only initiated under this agreement, Regatta shall advance the Company $125,000
as an advance to be reduced from the proceeds received from the first put.


 




    	 	- 3 -	 



     


    

 


(b) Payment for
Purchase Shares. For each Purchase, the Investor shall, on the Put Closing Date, pay to the Company an amount equal to the
Purchase Amount with respect to such Purchase as full payment for such Purchase Shares via wire transfer of immediately available
funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor
before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next
Business Day. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer any Purchase
Shares as DWAC Shares in respect of a Purchase within five (5) Business Days following the receipt by the Company of the Purchase
Price therefor in compliance with this Section 2(b), and if on or after such Business Day the Investor purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of such Purchase Shares that
the Investor anticipated receiving from the Company in respect of such Purchase, then the Company shall, within three (3) Business
Days after the Investor’s request, either (i) pay cash to the Investor in an amount equal to the Investor’s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Cover Price”),
at which point the Company’s obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii) promptly
honor its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal
to the excess (if any) of the Cover Price over the total Purchase Price for such Purchase. The Company shall not issue any fraction
of a share of Common Stock upon any Purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock,
the Company shall round such fraction of a share of Common Stock up or down (or, in the case of one-half (1/2) share, shall round
down) to the nearest whole share. All payments made under this Agreement shall be made by wire transfer of immediately available
funds to such account as the Company may from time to time designate by written notice in accordance with the provisions of this
Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day,
the same shall instead be due on the next succeeding day that is a Business Day.


 


(c)  Put Floor.
If on any Put Closing Date the Closing Market Price is less than the Floor Price (“Put Floor”), the Investor, in its
sole discretion, subject to the terms and conditions herein applicable to the Monthly Put, may accept or reject a Purchase under
this Agreement.


 


(d) Put by Mutual
Agreement. Notwithstanding the Put Ceiling or Put Floor for each Put, as described above, at any time either as a part of a
monthly Put or as an additional Put(s) during a month, the Company may request permission to request funds in excess of the Put
Ceiling or Put Floor for such month and may deliver to Investor(s) a Put or Puts in excess of the Put Ceiling, which Put or Puts
Investor(s) may fund, in its sole discretion, subject to the terms and conditions herein applicable to the monthly Puts.


 


(e) Compliance with
Rules of Principal Market.


 


(i) Exchange Cap.
Subject to Section 2(e)(ii) below, the Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and
the Investor shall not purchase or acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving
effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement would exceed the
maximum number of shares of Common Stock that the Company may issue pursuant to this Agreement and the transactions contemplated
hereby (taking into account all shares of Common Stock issued or issuable pursuant to any transaction or series of transactions
that may be aggregated with the transactions contemplated by this Agreement under applicable rules of The NASDAQ Stock Market)
without (A) breaching the Company’s obligations under the applicable rules of The NASDAQ Stock Market or (B) obtaining stockholder
approval under the applicable rules of The NASDAQ Stock Market (the “Exchange Cap”), unless and until the Company
elects to solicit stockholder approval of the transactions contemplated by this Agreement and the stockholders of the Company have
in fact approved the transactions contemplated by this Agreement in accordance with the applicable rules and regulations of The
NASDAQ Stock Market and the Certificate of Incorporation and Bylaws of the Company. For the avoidance of doubt, the Company may,
but shall be under no obligation to, request its stockholders to approve the transactions contemplated by this Agreement; provided,
that if stockholder approval is not obtained in accordance with this Section 2(e)(i), the Exchange Cap shall be applicable for
all purposes of this Agreement and the transactions contemplated hereby at all times during the term of this Agreement (except
as set forth in Section 2(e)(ii) below).


 


(ii) General.
The Company shall not issue any shares of Common Stock pursuant to this Agreement if such issuance would reasonably be expected
to result in (A) a violation of the Securities Act or (B) a breach of the rules and regulations of The NASDAQ Stock Market. The
provisions of this Section 2(e) shall be implemented in a manner otherwise than in strict conformity with the terms hereof only
if necessary to ensure compliance with the Securities Act and the rules and regulations of The NASDAQ Stock Market.


 


(f) Beneficial Ownership
Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell,
and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated
with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section
13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) would result in the beneficial ownership by the Investor
and its affiliates of more than 4.99% of the then issued and outstanding shares of Common Stock (the “Beneficial
Ownership Limitation”). Upon the written or oral request of the Investor, the Company shall promptly (but not later than
one (1) Business Day) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor
and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor’s
written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof
hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.


 


(g) Until the Commitment
Amount has been sold to Investor, the Company will pay to the Investor on the first of each month the sum of Thirty Thousand Dollars
($30,000).


 




    	 	- 4 -	 



     


    

 


		3.	INVESTOR'S REPRESENTATIONS AND WARRANTIES.



 


The Investor represents
and warrants to the Company that as of the date hereof and as of the Commencement Date:


 


(a) Accredited
Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation
D promulgated under the Securities Act.


 


(b) Information.
The Investor understands that its investment in the Purchase Shares involves a high degree of risk. The Investor (i) is able to
bear the economic risk of an investment in the Purchase Shares including a total loss thereof, (ii) has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Purchase
Shares and (iii) has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the
financial condition and business of the Company and others matters related to an investment in the Purchase Shares. Neither such
inquiries nor any other due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect
the Investor’s right to rely on the Company's representations and warranties contained in Section 4 below. The Investor has
sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Purchase Shares.


 


(c) No Governmental
Review. The Investor understands that no U.S. federal or state agency or any other government or governmental agency has passed
on or made any recommendation or endorsement of the Purchase Shares or the fairness or suitability of an investment in the Purchase
Shares nor have such authorities passed upon or endorsed the merits of the offering of the Purchase Shares.


 


(d) Validity; Enforcement.
This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid and binding
agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability to general
principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating
to, or affecting generally, the enforcement of applicable creditors' rights and remedies. The execution and delivery of the Transaction
Documents by the Investor and the consummation by it of the transactions contemplated hereby do not conflict with the Investor’s
certificate of organization or operating agreement or similar documents, and do not require further consent or authorization by
the Investor, its managers or its members.


 


		4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.



 


Except as set forth
in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise
made herein, the Company represents and warrants to the Investor that as of the date hereof and as of the Commencement Date:


 


(a) Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of formation or
incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified
to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of
the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no
proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification. The Company has no Subsidiaries except as set forth on Schedule 4(a).


 




    	 	- 5 -	 



     


    

 


(b) Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and each of the other Transaction Documents, and to issue the Purchase Shares in accordance with the terms
hereof and thereof, (ii) the execution and delivery of the Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby, including without limitation, the reservation for issuance and the issuance of the
Purchase Shares issuable under this Agreement, have been duly authorized by the Company's Board of Directors and no further consent
or authorization is required by the Company, its Board of Directors or its stockholders, (iii) this Agreement has been, and each
other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this Agreement
constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding
obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be
limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
laws relating to, or affecting generally, the enforcement of creditors' rights and remedies. The Board of Directors of the Company
has approved the resolutions (the “Signing Resolutions”) substantially in the form as set forth as Exhibit
A attached hereto to authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions are valid,
in full force and effect and have not been modified or supplemented in any respect. The Company has delivered to the Investor a
true and correct copy of signed minutes of a meeting of the Board of Directors of the Company at which the Signing Resolutions
were duly adopted by the Board of Directors or a unanimous written consent adopting the Signing Resolutions executed by all of
the members of the Board of Directors of the Company. Except as set forth in this Agreement, no other approvals or consents of
the Company’s Board of Directors and/or stockholders is necessary under applicable laws and the Company’s Certificate
of Incorporation and/or Bylaws to authorize the execution and delivery of this Agreement or any of the transactions contemplated
hereby, including, but not limited to, the issuance of the Purchase Shares.


 


(c) Capitalization.
As of the date hereof, the authorized capital stock of the Company is set forth on Schedule 4(c). Except as disclosed in
Schedule 4(c), (i) no shares of the Company's capital stock are subject to preemptive rights or any other similar rights
or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt securities, (iii) there are
no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional
shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the
Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries
is obligated to register the sale of any of their securities under the Securities Act, (v) there are no outstanding securities
or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a
security of the Company or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar
provisions that will be triggered by the issuance of the Purchase Shares as described in this Agreement and (vii) the Company does
not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. The
Company has furnished to the Investor true and correct copies of the Company's Certificate of Incorporation, as amended and as
in effect on the date hereof (the “Certificate of Incorporation”), and the Company's Bylaws, as amended and
as in effect on the date hereof (the “Bylaws”), and summaries of the terms of all securities convertible into
or exercisable for Common Stock, if any, and copies of any documents containing the material rights of the holders thereof in respect
thereto.


 


(d) Issuance of
Purchase Shares. Upon issuance and payment thereof in accordance with the terms and conditions of this Agreement, the Purchase
Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of first
refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder
of Common Stock. 3,700,000 shares of Common Stock have been duly authorized and reserved for issuance upon purchase under this
Agreement as Purchase Shares.


 


(e) No Conflicts.
The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance and issuance of the Purchase
Shares) will not (i) result in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences and
Rights of any outstanding series of preferred stock of the Company or the Bylaws or (ii) conflict with, or constitute a default
(or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries
is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and the rules and regulations of the Principal Market applicable to the Company or any of its Subsidiaries)
or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts,
defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which would not reasonably be
expected to result in a Material Adverse Effect. Neither the Company nor its Subsidiaries is in violation of any term of or in
default under its Certificate of Incorporation, any Certificate of Designation, Preferences and Rights of any outstanding series
of preferred stock of the Company or Bylaws or their organizational charter or Bylaws, respectively. Neither the Company nor any
of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness,
indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries,
except for possible conflicts, defaults, terminations or amendments which could not reasonably be expected to have a Material Adverse
Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any
law, ordinance, regulation of any governmental entity, except for possible violations, the sanctions for which either individually
or in the aggregate could not reasonably be expected to have a Material Adverse Effect. Except as specifically contemplated by
this Agreement and as required under the Securities Act or applicable state securities laws and the rules and regulations of the
Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration
with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform
any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof. Except
as set forth elsewhere in this agreement, all consents, authorizations, orders, filings and registrations which the Company is
required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Since
one year prior to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal
Market other than notices with respect to listings of additional shares of Common Stock and other routine correspondence. Other
than as set forth on Schedule 4(e), to the knowledge of the Company, the Principal Market has not commenced any delisting
proceedings against the Company.


 




    	 	- 6 -	 



     


    

 


(f) SEC Documents;
Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed
by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve
months preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their
respective dates and to the Company’s knowledge, the SEC Documents complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations
of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. Except as publicly
available through the SEC’s Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) or in connection with a confidential
treatment request submitted to the SEC, the Company has received no notices or correspondence from the SEC for the one year preceding
the date hereof other than SEC comment letters relating to the Company’s filings under the Exchange Act and the Securities
Act. Except as disclosed in Schedule 4(f), there are no “open” SEC comments. The SEC has not commenced any enforcement
proceedings against the Company or any of its Subsidiaries.


 


(g) Absence of
Certain Changes. Except as disclosed in Schedule 4(g), since December 31, 2015, there has been no material adverse change
in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries. The Company
has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor
does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary
bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become
due.


 


(h) Absence of
Litigation. Except as disclosed in Schedule 4(h), there is no action, suit, proceeding, inquiry or investigation before
or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company
or any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company's Subsidiaries
or any of the Company's or the Company's Subsidiaries' officers or directors in their capacities as such, which would reasonably
be expected to have a Material Adverse Effect.


 


(i) Acknowledgment
Regarding Investor's Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm's
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further
acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor
or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and
thereby is merely incidental to the Investor's purchase of the Purchase Shares. The Company further represents to the Investor
that the Company's decision to enter into the Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives and advisors.


 


(j) No Integrated
Offering. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering of the Purchase Shares to be integrated with prior offerings by the Company in a manner that would require stockholder
approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed or designated.
The issuance and sale of the Purchase Shares hereunder does not contravene the rules and regulations of the Principal Market.


 




    	 	- 7 -	 



     


    

 


(k) Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
Except as disclosed in Schedule 4(k), none of the Company's material trademarks, trade names, service marks, service mark
registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade
secrets or other intellectual property rights have expired or terminated, or, by the terms and conditions thereof, could expire
or terminate within two years from the date of this Agreement. The Company and its Subsidiaries do not have any knowledge of any
infringement by the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights,
inventions, licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others,
or of any such development of similar or identical trade secrets or technical information by others and there is no claim, action
or proceeding being made or brought against, or to the Company's knowledge, being threatened against, the Company or its Subsidiaries
regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark
registrations, trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect.


 


(l) Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local
laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants (“ Environmental Laws”), (ii) have received all permits, licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance
with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the
failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.


 


(m) Title.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case
free and clear of all liens, encumbrances and defects (“Liens”) and, except for Liens as do not materially affect
the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company
and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor
subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance with such exceptions as
are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and
its Subsidiaries.


 


(n) Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings,
business or operations of the Company and its Subsidiaries, taken as a whole.


 


(o) Regulatory
Permits. The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to
possess such permits could not reasonably be expected to result in a Material Adverse Effect, and neither the Company nor any such
Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization
or permit.


 


(p) Tax Status.
The Company and each of its Subsidiaries has made or filed all federal and state income and all other material tax returns, reports
and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of
its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes)
and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the
officers of the Company know of no basis for any such claim.


 


(q) Transactions
With Affiliates. Except as set forth in the SEC Documents, since January 1, 2014, the Company has had no transaction with any
related person required to be disclosed by the Company in accordance with Item 404 of Regulation S-K promulgated by the SEC.


 


(r) Application
of Takeover Protections. The Company and its Board of Directors have taken or will take prior to the Commencement Date all
necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the
laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company's issuance of the Purchase Shares and the Investor's ownership of
the Purchase Shares.


 




    	 	- 8 -	 



     


    

 


(s)  Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents that will
be timely publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has
provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material,
non-public information which is not otherwise disclosed in the Registration Statement or any Prospectus Supplements thereto. The
Company understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of
securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company,
its business and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true and correct
in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press
releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3 hereof.


 


(t) Foreign Corrupt
Practices. Neither the Company, nor to the knowledge of the Company, any agent or other Person acting on behalf of the Company,
has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related
to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees
or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution
made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation of law, or
(iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.


 


(u) Registration
Statement. The Company has prepared and filed with the SEC in accordance with the provisions of the Securities Act the Registration
Statement. The Registration Statement was declared effective by order of the SEC on October 28, 2014. The Registration Statement
is effective pursuant to the Securities Act and available for the issuance of the Purchase Shares thereunder, and the Company has
not received any written notice that the SEC has issued or intends to issue a stop order or other similar order with respect to
the Registration Statement or the Prospectus or that the SEC otherwise has (i) suspended or withdrawn the effectiveness of
the Registration Statement or (ii) issued any order preventing or suspending the use of the Prospectus or any Prospectus Supplement,
in either case, either temporarily or permanently or intends or has threatened in writing to do so. The “Plan of Distribution”
section of the Prospectus permits the issuance of the Purchase Shares hereunder. At the time the Registration Statement and any
amendments thereto became effective, at the date of this Agreement and at each deemed effective date thereof pursuant to Rule 430B(f)(2)
of the Securities Act, the Registration Statement and any amendments thereto complied and will comply in all material respects
with the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Base
Prospectus and any Prospectus Supplement thereto, at the time such Base Prospectus or such Prospectus Supplement thereto was issued
and on the Commencement Date, complied and will comply in all material respects with the requirements of the Securities Act and
did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading; provided that this representation
and warranty does not apply to statements in or omissions from any Prospectus Supplement made in reliance upon and in conformity
with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use
therein. The Company meets all of the requirements for the use of a registration statement on Form S-3 pursuant to the Securities
Act for the offering and sale of the Purchase Shares contemplated by this Agreement and the SEC has not notified the Company of
any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(1) of the Securities Act. The Registration
Statement, as of its effective date, meets the requirements set forth in Rule 415(a)(1)(x) pursuant to the Securities Act. At the
earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide
offer (within the meaning of Rule 164(h)(2) of the Securities Act) relating to any of the Purchase Shares, the Company was not
and is not an Ineligible Issuer (as defined in Rule 405 of the Securities Act). The Company has not distributed any offering material
in connection with the offering and sale of any of the Purchase Shares, and, until the Investor does not hold any of the Purchase
Shares, shall not distribute any offering material in connection with the offering and sale of any of the Purchase Shares, to or
by the Investor, in each case, other than the Registration Statement or any amendment thereto, the Prospectus or any Prospectus
Supplement required pursuant to applicable law or the Transaction Documents. The Company has not made, and agrees that unless it
obtains the prior written consent of the Investor it will not make, an offer relating to the Purchase Shares that could constitute
a “free writing prospectus” as defined in Rule 405 under the Securities Act. The Company shall comply with the requirements
of Rules 164 and 433 under the Securities Act applicable to any such free writing prospectus consented to by the Investor, including
in respect of timely filing with the SEC, legending and record keeping.


 


(v) DTC Eligibility.
The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and
the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.


 




    	 	- 9 -	 



     


    

 


(w) Sarbanes-Oxley.
The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it as of
the date hereof.


 


(x) Certain Fees.
No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction
Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of
other Persons for any fees that may be due in connection with the transactions contemplated by the Transaction Documents.


 


(y) Investment
Company. The Company is not, and immediately after receipt of payment for the Purchase Shares will not be, an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.


 


(z) Listing and
Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating
terminating such registration. Except as disclosed in Schedule 4(z), the Company has not, in the twelve (12) months preceding
the date hereof, received any notice from the Principal Market to the effect that the Company is not in compliance with the listing
or maintenance requirements of the Principal Market. Except as disclosed in Schedule 4(z), the Company is in compliance
with all such listing and maintenance requirements.


 


(aa) Accountants.
The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are an
independent registered public accounting firm as required by the Securities Act.


 


(bb) No Market
Manipulation. The Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Purchase Shares, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Purchase Shares, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company.


 


(cc) Shell Company
Status. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the Securities Act.


 


		5.	COVENANTS.



 


(a) Filing of Current
Report and Initial Prospectus Supplement. The Company agrees that it shall, within the time required under the Exchange Act,
file with the SEC a report on Form 8-K relating to the transactions contemplated by, and describing the material terms and conditions
of, the Transaction Documents (the “Current Report”). The Company further agrees that it shall, within the time
required under Rule 424(b) under the Securities Act, file with the SEC the Initial Prospectus Supplement pursuant to Rule 424(b)
under the Securities Act specifically relating to the transactions contemplated by, and describing the material terms and conditions
of, the Transaction Documents, containing information previously omitted at the time of effectiveness of the Registration Statement
in reliance on Rule 430B under the Securities Act, and disclosing all information relating to the transactions contemplated hereby
required to be disclosed in the Registration Statement and the Prospectus as of the date of the Initial Prospectus Supplement,
including, without limitation, information required to be disclosed in the section captioned “Plan of Distribution”
in the Prospectus. The Investor acknowledges that it will be identified in the Initial Prospectus Supplement as an underwriter
within the meaning of Section 2(a)(11) of the Securities Act. The Company shall permit the Investor to review and comment upon
the Current Report and the Initial Prospectus Supplement at least two (2) Business Days prior to their filing with the SEC, the
Company shall give due consideration to all such comments, and the Company shall not file the Current Report or the Initial Prospectus
Supplement with the SEC in a form to which the Investor reasonably objects. The Investor shall use its reasonable best efforts
to comment upon the Current Report and the Initial Prospectus Supplement within one (1) Business Day from the date the Investor
receives the final pre-filing draft version thereof from the Company. The Investor shall furnish to the Company such information
regarding itself, the Purchase Shares held by it and the intended method of distribution thereof, including any arrangement between
the Investor and any other Person relating to the sale or distribution of the Purchase Shares, as shall be reasonably requested
by the Company in connection with the preparation and filing of the Current Report and the Initial Prospectus Supplement, and shall
otherwise cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of the
Current Report and the Initial Prospectus Supplement with the SEC.


 


(b) Blue Sky.
The Company shall take all such action, if applicable, as is reasonably necessary in order to obtain an exemption for or to register
or qualify (i) the issuance of the sale of the Purchase Shares to the Investor under this Agreement and (ii) any subsequent resale
of the Purchase Shares by the Investor, in each case, under applicable securities or “Blue Sky” laws of the states
of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence of
any such action so taken to the Investor.


 




    	 	- 10 -	 



     


    

 


(c) Listing/DTC.
The Company shall promptly secure the listing of all of the Purchase Shares to be issued to the Investor hereunder on the Principal
Market (subject to official notice of issuance) and upon each other national securities exchange or automated quotation system,
if any, upon which the Common Stock is then listed, and shall use commercially reasonable efforts to maintain, so long as any shares
of Common Stock shall be so listed, such listing of all such Purchase Shares from time to time issuable hereunder. The Company
shall use commercially reasonable efforts to maintain the listing of the Common Stock on the Principal Market and shall comply
in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules and regulations of the
Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be expected to result
in the delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event later than
the following Business Day, provide to the Investor copies of any notices it receives from the Principal Market regarding the continued
eligibility of the Common Stock for listing on the Principal Market; provided, however, that the Company shall not be required
to provide the Investor copies of any such notice that the Company reasonably believes constitutes material non-public information
and the Company would not be required to publicly disclose such notice in any report or statement filed with the SEC under the
Exchange Act (including on Form 8-K) or the Securities Act. The Company shall pay all fees and expenses in connection with satisfying
its obligations under this Section 5(c). The Company shall take all action necessary to ensure that its Common Stock can
be transferred electronically as DWAC Shares.


 


(d) Prohibition
of Short Sales and Hedging Transactions. The Investor agrees that beginning on the date of this Agreement and ending on the
next Business Date following the termination of this Agreement as provided in Section 11, the Investor and its agents, representatives
and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short sale”
(as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which
establishes a net short position with respect to the Common Stock.


 


(e) Sale
of New Securities. During the Term, and for a period of one (1) year thereafter, if the Company executes an agreement
to sell any New Security (as hereinafter defined) of the Company to any third party, at a lower price than the Purchase Price
paid by Investor in connection with the Prior Purchase (as defined below), whether or not such equity securities are
currently authorized or designated, as well as any rights, options, or warrants to purchase such equity securities, and any
securities of any type whatsoever that is, or may become, convertible or exchangeable into or exercisable for such equity
securities, then the Company upon each such offering of the New Securities will pay an aggregate of $30,000 to Investor. For
the purposes of this Agreement, “New Security” shall mean any fixed price equity securities of the Company
sold within (meaning either before or after) 15 days of a Purchase (“Prior Purchase”). For purposes of clarity, an
offering means the sale by the Company of securities in one transaction regardless of the number of investors or closing
dates provided such closing dates are within five (5) business days of each other. Closings beyond such five (5) business
days of each other will be considered a new offering as it relates to the $30,000 fee.


 


(f) Due Diligence;
Non-Public Information. The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate
and upon reasonable advance notice to the Company, to perform reasonable due diligence on the Company during normal business hours.
The Company and its officers and employees shall provide information and reasonably cooperate with the Investor in connection with
any reasonable request by the Investor related to the Investor's due diligence of the Company. Each party hereto agrees not to
disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for
any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges
that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable
measures to protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither
it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes
or might constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company
in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the Company or any Person acting
on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein
or in the other Transaction Documents, the Investor shall have the right to make a public disclosure, in the form of a press release,
public advertisement or otherwise, of such material, non-public information without the prior approval by the Company; provided
the Investor shall have first provided notice to the Company that it believes it has received information that constitutes material,
non-public information, the Company shall have up to 24 hours to publicly disclose such material, non-public information prior
to any such disclosure by the Investor, and the Company shall have failed to publicly disclose such material, non-public information
within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective
directors, officers, employees, stockholders or agents, for any such disclosure. The Company understands and confirms that the
Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company.


 


(g)  Purchase
Records. The Investor and the Company shall each maintain records showing the remaining Available Shares at any given time
and the dates and Purchase Amounts for each Purchase or shall use such other method, reasonably satisfactory to the Investor and
the Company.


 




    	 	- 11 -	 



     


    

 


(h) Taxes.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investor made under this Agreement.


 


(i) Effective Registration
Statement; Current Prospectus; Securities Law Compliance. The Company shall use its reasonable best efforts to keep the Registration
Statement effective pursuant to Rule 415 promulgated under the Securities Act, and to keep the Registration Statement and the Prospectus
current and available for issuances and sales of all of the Purchase Shares by the Company to the Investor, and for the resale
by the Investor, at all times until the earlier of (i) the date on which the Investor shall have sold all the Purchase Shares and
no Available Share remains under this Agreement and (ii) 90 days following the Maturity Date (the “Registration Period”).
Without limiting the generality of the foregoing, during the Registration Period, the Company shall (a) take all action necessary
to cause the Common Stock to continue to be registered as a class of securities under Sections 12(b) of the Exchange Act, shall
comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file any document (whether
or not permitted by the Exchange Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing
obligations under the Exchange Act, and (b) prepare and file with the SEC, at the Company’s expense, such amendments (including,
without limitation, post-effective amendments) to the Registration Statement and such Prospectus Supplements pursuant to Rule 424(b)
under the Securities Act, in each case, as may be necessary to keep the Registration Statement effective pursuant to Rule 415 promulgated
under the Securities Act, and to keep the Registration Statement and the Prospectus current and available for issuances and sales
of all of the Purchase Shares by the Company to the Investor, at all times during the Registration Period (it being hereby acknowledged
and agreed that the Company shall prepare and file with the SEC, at the Company’s expense, immediately prior to the third
anniversary of the initial effective date of the Registration Statement (the “Renewal Date”), a new Registration
Statement relating to the Purchase Shares, in a form satisfactory to the Investor and its counsel, and the Company shall use its
reasonable best efforts to cause such Registration Statement to be declared effective within 90 days after the Renewal Date unless
the Registration Period has lapsed). The Investor shall furnish to the Company such information regarding itself, the Purchase
Shares held by it and the intended method of distribution thereof as shall be reasonably requested by the Company in connection
with the preparation and filing of any such amendment to the Registration Statement (or new Registration Statement) or any such
Prospectus Supplement, and shall otherwise cooperate with the Company as reasonably requested by the Company in connection with
the preparation and filing of any such amendment to the Registration Statement (or new Registration Statement) or any such Prospectus
Supplement. The Company shall comply with all applicable federal, state and foreign securities laws in connection with the offer,
issuance and sale of the Purchase Shares contemplated by the Transaction Documents. Without limiting the generality of the foregoing,
neither the Company nor any of its officers, directors or affiliates will take, directly or indirectly, any action designed or
intended to stabilize or manipulate the price of any security of the Company, or which would reasonably be expected to cause or
result in, stabilization or manipulation of the price of any security of the Company.


 


(j) Stop Orders.
The Company shall advise the Investor promptly (but in no event later than 24 hours) and shall confirm such advice in writing:
(i) of the Company’s receipt of notice of any request by the SEC for amendment of or a supplement to the Registration Statement,
the Prospectus, any Prospectus Supplement or for any additional information with respect thereto; (ii) of the Company’s receipt
of notice of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or prohibiting
or suspending the use of the Prospectus or any Prospectus Supplement, or of the Company’s receipt of any notification of
the suspension of qualification of the Purchase Shares for offering or sale in any jurisdiction or the initiation or contemplated
initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes
any statement of a material fact made in the Registration Statement, the Prospectus or any Prospectus Supplement untrue or which
requires the making of any additions to or changes to the statements then made in the Registration Statement, the Prospectus or
any Prospectus Supplement in order to state a material fact required by the Securities Act to be stated therein or necessary in
order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances
under which they were made) not misleading, or of the necessity to amend the Registration Statement or supplement the Prospectus
or any Prospectus Supplement to comply with the Securities Act or any other law. The Company shall not be required to disclose
to the Investor the substance or specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately
preceding sentence, but rather, shall only be required to disclose that the event has occurred. The Company shall not deliver to
the Investor any Put Notice, and the Investor shall not be obligated to purchase any shares of Common Stock under this Agreement,
during the continuation or pendency of any of the foregoing events. If at any time the SEC shall issue any stop order suspending
the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement,
the Company shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest possible time. The Company
shall furnish to the Investor, without charge, a copy of any correspondence from the SEC or the staff of the SEC to the Company
or its representatives relating to the Registration Statement or the Prospectus, as the case may be.


 




    	 	- 12 -	 



     


    

 


(k) Amendments
to Registration Statement; Prospectus Supplements. Except as provided in this Agreement and other than periodic and current
reports required to be filed pursuant to the Exchange Act, the Company shall not file with the SEC any amendment to the Registration
Statement or any supplement to the Base Prospectus that refers to the Investor, the Transaction Documents or the transactions contemplated
thereby (including, without limitation, any Prospectus Supplement filed in connection with the transactions contemplated by the
Transaction Documents), in each case with respect to which (a) the Investor shall not previously have been advised and afforded
the opportunity to review and comment thereon at least two (2) Business Days prior to filing with the SEC, (b) the Company shall
not have given due consideration to any comments thereon received from the Investor or its counsel, or (c) the Investor shall reasonably
object, unless the Company reasonably has determined that it is necessary to amend the Registration Statement or make any supplement
to the Prospectus to comply with the Securities Act or any other applicable law or regulation, in which case the Company shall
promptly (but in no event later than 24 hours) so inform the Investor, the Investor shall be provided with a reasonable opportunity
to review and comment upon any disclosure referring to the Investor, the Transaction Documents or the transactions contemplated
thereby, as applicable, and the Company shall expeditiously furnish to the Investor a copy thereof. In addition, for so long as,
in the reasonable opinion of counsel for the Investor, the Prospectus is required to be delivered in connection with any acquisition
or sale of Purchase Shares by the Investor, the Company shall not file any Prospectus Supplement with respect to the Purchase Shares
without furnishing to the Investor as many copies of such Prospectus Supplement, together with the Prospectus, as the Investor
may reasonably request.


 


(l) Prospectus
Delivery. The Company consents to the use of the Prospectus (and of each Prospectus Supplement thereto) in accordance with
the provisions of the Securities Act and with the securities or “blue sky” laws of the jurisdictions in which the Purchase
Shares may be sold by the Investor, in connection with the offering and sale of the Purchase Shares and for such period of time
thereafter as the Prospectus is required by the Securities Act to be delivered in connection with sales of the Purchase Shares.
The Company will make available to the Investor upon request, and thereafter from time to time will furnish to the Investor, as
many copies of the Prospectus (and each Prospectus Supplement thereto) as the Investor may reasonably request for the purposes
contemplated by the Securities Act within the time during which the Prospectus is required by the Securities Act to be delivered
in connection with sales of the Purchase Shares. If during such period of time any event shall occur that in the reasonable judgment
of the Company and its counsel, or in the reasonable judgment of the Investor and its counsel, is required to be set forth in the
Registration Statement, the Prospectus or any Prospectus Supplement or should be set forth therein in order to make the statements
made therein (in the case of the Prospectus or any Prospectus Supplement, in light of the circumstances under which they were made)
not misleading, or if in the reasonable judgment of the Company and its counsel, or in the reasonable judgment of the Investor
and its counsel, it is otherwise necessary to amend the Registration Statement or supplement the Prospectus or any Prospectus Supplement
to comply with the Securities Act or any other applicable law or regulation, the Company shall forthwith prepare and, subject to
Section 5(k) above, file with the SEC an appropriate amendment to the Registration Statement or an appropriate Prospectus Supplement
and in each case shall expeditiously furnish to the Investor, at the Company’s expense, such amendment to the Registration
Statement or such Prospectus Supplement, as applicable, as may be necessary to reflect any such change or to effect such compliance.
The Company shall have no obligation to separately advise the Investor of, or deliver copies to the Investor of, the SEC Documents,
all of which the Investor shall be deemed to have notice of.


 


(m) Integration.
From and after the date of this Agreement, the Company will not, and will use its reasonable best efforts to ensure that no Person
acting on its behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security,
under circumstances that would cause this offering of the Purchase Shares to be integrated with other offerings by the Company
in a manner that would require stockholder approval pursuant to the rules of the Principal Market on which any of the securities
of the Company are listed or designated, unless stockholder approval is obtained before the closing of such subsequent transaction
in accordance with the rules of such Principal Market.


 


(n) Use of Proceeds.
The Company will use the net proceeds from the offering as described in the Prospectus Supplement.


 


(o) Other Transactions.
The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in
or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to
perform its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver
the Purchase Shares to the Investor in accordance with the terms of the Transaction Documents.


 


(p) Required Filings
Relating to Purchases. To the extent required under the Securities Act or under interpretations by the SEC thereof, as promptly
as practicable after the close of each of the Company’s fiscal quarters (or on such other dates as required under the Securities
Act or under interpretations by the SEC thereof), the Company shall prepare a Prospectus Supplement, which will set forth the number
of Purchase Shares sold to the Investor during such quarterly period (or other relevant period), the purchase price for such Purchase
Shares and the net proceeds received by the Company from such sales, and shall file such Prospectus Supplement with the SEC pursuant
to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities
Act). If any such quarterly Prospectus Supplement is not required to be filed under the Securities Act or under interpretations
by the SEC thereof, the Company shall disclose the information referenced in the immediately preceding sentence in its annual report
on Form 10-K or its quarterly report on Form 10-Q (as applicable) in respect of the quarterly period that ended immediately before
the filing of such report in which sales of Purchase Shares were made to the Investor under this Agreement, and file such report
with the SEC within the applicable time period required by the Exchange Act. The Company shall not file any Prospectus Supplement
pursuant to this Section 5(p), and shall not file any report containing disclosure relating to such sales of Purchase Shares, unless
a copy of such Prospectus Supplement or disclosure has been submitted to the Investor a reasonable period of time before the filing
and the Investor has not reasonably objected thereto (it being acknowledged and agreed that the Company shall not submit any portion
of any Form 10-K or Form 10-Q other than the specific disclosure relating to any sales of Purchase Shares). The Company shall also
furnish copies of all such Prospectus Supplements to each exchange or market in the United States on which sales of the Purchase
Shares may be made as may be required by the rules or regulations of such exchange or market, if applicable.


 




    	 	- 13 -	 



     


    

 


(q) No Variable
Rate Transactions. From the date of this Agreement until the earlier of the Maturity Date or the date of termination of this
Agreement, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or
any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) for cash consideration
involving a Variable Rate Transaction, other than in connection with an Exempt Issuance. “Common Stock Equivalents”
means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time shares of Common
Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock.
“Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity
securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common
Stock or Common Stock Equivalents either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such
debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date
after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or
indirectly related to the business of the Company or the market for the Common Stock (including, without limitation, any “full
ratchet” or “weighted average” anti-dilution provisions) or (ii) enters into any agreement, including, but not
limited to, an “equity line of credit,” “at-the-market offering” or other continuous offering or similar
offering of Common Stock or Common Stock Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at
a future determined price. “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to
employees, officers, directors, consultants or vendors of the Company pursuant to any stock or option plan duly adopted for such
purpose, by the Board of Directors or a majority of the members of a committee of directors established for such purpose, (b) securities
upon the exercise or exchange of or conversion of any Purchase Shares issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities
have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price,
exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions or strategic transactions
approved by the Board of Directors or a majority of the members of a committee of directors established for such purpose, which
acquisitions or strategic transactions can have a Variable Rate Transaction component, provided that any such issuance shall only
be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an
asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition
to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities, and (d) with the Investor’s prior written
consent, which shall not be unreasonably withheld, warrants issued as part of units of securities issued by the Company in a firm-commitment
underwritten public offering that contain customary “weighted-average” exercise price anti-dilution provisions (it
being hereby acknowledged and agreed that this Agreement shall not be deemed to constitute the Investor’s prior written consent
thereto).


 


(r) Purchase Price
Reset. At any time within ten (10) business days of each Put Closing Date, in the event that the Company issues or sells any
shares of Common Stock or any Common Stock equivalent (calculated on an as converted, as exercised basis) pursuant to which shares
of Common Stock may be acquired at a price less than the Purchase Price (a “Share Dilutive Issuance”), other
than to Investor, then the Company shall promptly issue additional shares of Common Stock to the Investor for no additional consideration,
in an amount sufficient that (a) the aggregate Purchase Price paid at each such Put Closing Date, when divided by (x) the sum of
(i) the total number of Shares to be sold to the Investor on the date of such Dilutive Issuance, (ii) any other shares of Common
Stock then or theretofore issued in respect of such Shares (by stock split, stock dividend or otherwise) that resulted in an adjustment
to the per share Purchase Price referred to above, and (iii) all Additional Shares (defined below) issued with respect to such
shares sold to the Investor on the date of such Share Dilutive Issuance that were issued as a result of Share Dilutive Issuances
that occurred prior to such Share Dilutive Issuance, will equal the price per share of Common Stock in such Share Dilutive Issuance
(each such adjustment, a “Share Dilution Adjustment”, and such shares, the “Additional Shares”).
Such Share Dilution Adjustment shall be made successively whenever such an issuance is made. Such Additional Shares must be delivered
to the Investor not later than the date the Share Dilutive Issuance occurs. Notwithstanding the foregoing, this Section 5(r) shall
not apply in respect of an Exempt Issuance. No adjustment shall be made hereunder which would require the Investor to surrender
any shares to the Company. The holder of outstanding Additional Shares is granted the same rights and benefits as a holder of outstanding
shares pursuant to this Agreement except the rights and benefits of this Section 5(r) and except that such rights and benefits
shall not apply to a holder of outstanding Additional Shares after such outstanding Additional Share has been irrevocably sold
pursuant to an effective registration statement under the Securities Act or pursuant to Rule 144 without further restrictions or
conditions to transfer pursuant to Rule 144.


 




    	 	- 14 -	 



     


    

 


		6.	TRANSFER AGENT INSTRUCTIONS.



 


On the date of this
Agreement, the Company shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions, in the form
substantially similar to those used by the Investor in substantially similar transactions, to issue the Purchase Shares in accordance
with the terms of this Agreement (the “Irrevocable Transfer Agent Instructions”). All Purchase Shares to be
issued to or for the benefit of the Investor pursuant to this Agreement shall be issued as DWAC Shares. The Company warrants to
the Investor that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 6 will be given
by the Company to the Transfer Agent with respect to the Purchase Shares, and the Purchase Shares shall otherwise be freely transferable
on the books and records of the Company.


 


		7.	CONDITIONS TO THE COMPANY'S RIGHT TO COMMENCE SALES
OF SHARES OF COMMON STOCK.



 


The right of the Company
hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction or, where legally permissible,
the waiver of each of the following conditions:


 


(a) The Investor shall
have executed each of the Transaction Documents and delivered the same to the Company;


 


(b) No stop order
with respect to the Registration Statement shall be pending or threatened by the SEC and the Initial Prospectus Supplement shall
have been delivered to the Investor;


 


(c) All federal, state,
local and foreign governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction Documents
and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders
of, and all filings and registrations with, all federal, state, local and foreign courts or governmental agencies and all federal,
state, local and foreign regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction
Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained
or made, including, without limitation, in each case those required prior to the commencement of sales of Purchase Shares under
the Securities Act, the Exchange Act, applicable state securities or “Blue Sky” laws or applicable rules and regulations
of the Principal Market or otherwise required by the SEC, the Principal Market, or any state securities regulators;


 


(d) No statute, regulation,
order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal,
state or local court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially
modify or delay any of the transactions contemplated by the Transaction Documents;


 


(e) If applicable,
all Purchase Shares to be issued by the Company to the Investor under the Transaction Documents shall have been approved for listing
on the Principal Market in accordance with the applicable rules and regulations of the Principal Market, subject only to official
notice of issuance; and


 


(f) The representations
and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as of the Commencement
Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true
and correct in all material respects as of such specific date) and the Investor shall have performed, satisfied and complied in
all material respects with the covenants and agreements required by this Agreement to be performed, satisfied or complied with
by the Investor at or prior to the Commencement Date.


 


		8.	CONDITIONS TO THE INVESTOR'S OBLIGATION TO PURCHASE
SHARES OF COMMON STOCK.



 


The obligation of
the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction or, where legally permissible, the waiver
of each of the following conditions on or prior to the Commencement Date:


 


(a) The Company shall
have executed each of the Transaction Documents and delivered the same to the Investor;


 


(b) The Common Stock
shall be listed on the Principal Market and all Purchase Shares to be issued by the Company to the Investor pursuant to this Agreement
shall have been, if applicable, approved for listing on the Principal Market in accordance with the applicable rules and regulations
of the Principal Market, subject only to official notice of issuance;


 


(c) The Investor shall
have received the opinion of the Company's legal counsel dated as of the Commencement Date substantially in the forms agreed to
prior to the date of this Agreement by the Company’s legal counsel and the Investor’s legal counsel;


 


(d) The representations
and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such representations
and warranties is already qualified as to materiality in Section 4 above, in which case, such representations and warranties shall
be true and correct without further qualification) as of the date when made and as of the Commencement Date as though made at that
time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied
and complied with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or
complied with by the Company at or prior to the Commencement Date. The Investor shall have received a certificate, executed by
the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto
as Exhibit B;


 




    	 	- 15 -	 



     


    

 


(e) The Board of Directors
of the Company shall have adopted resolutions in the form attached hereto as Exhibit A which shall be in full force
and effect without any amendment or supplement thereto as of the Commencement Date;


 


(f) As of the Commencement
Date, the Company shall have reserved out of its authorized and unissued Common Stock, solely for the purpose of effecting purchases
of Purchase Shares hereunder, 3,700,000 shares of Common Stock;


 


(g) The Irrevocable
Transfer Agent Instructions shall have been delivered to and acknowledged in writing by the Company and the Transfer Agent (or
any successor transfer agent);


 


(h) The Company shall
have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in the State of Delaware
issued by the Secretary of State of the State of Delaware as of a date within five (5) Business Days of the Commencement Date;


 


(i) The Company shall
have delivered to the Investor a certified copy of the Certificate of Incorporation as certified by the Secretary of State of the
State of Delaware within five (5) Business Days of the Commencement Date;


 


(j) The Company shall
have delivered to the Investor a secretary's certificate executed by the Secretary of the Company, dated as of the Commencement
Date, in the form attached hereto as Exhibit C;


 


(k) The Registration
Statement shall continue to be effective and no stop order with respect to the Registration Statement shall be pending or threatened
by the SEC. The Current Report and the Initial Prospectus Supplement each shall have been filed with the SEC, as required pursuant
to Section 5(a), and copies of the Prospectus shall have been delivered to the Investor in accordance with Section 5(m) hereof.
The Prospectus shall be current and available for issuances and sales of all of the Purchase Shares by the Company to the Investor,
and for the resale of all of the Purchase Shares by the Investor. Any other Prospectus Supplements required to have been filed
by the Company with the SEC under the Securities Act at or prior to the Commencement Date shall have been filed with the SEC within
the applicable time periods prescribed for such filings under the Securities Act. All reports, schedules, registrations, forms,
statements, information and other documents required to have been filed by the Company with the SEC at or prior to the Commencement
Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable time periods
prescribed for such filings under the Exchange Act;


 


(l) No Event of Default
(as defined below) has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred;


 


(m) All federal, state
and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction Documents and
necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated
thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders of, and
all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state and local
regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the
consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made, including,
without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state securities or “Blue
Sky” laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market
or any state securities regulators;


 


(n) No statute, regulation,
order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal,
state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation of or which
would materially modify or delay any of the transactions contemplated by the Transaction Documents; and


 


(o) No action, suit
or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent jurisdiction
shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental authority
of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors or affiliates
of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking material
damages in connection with such transactions.


 


(p) Upon execution
of this Agreement, the Company shall reimburse Investor Forty Thousand Dollars ($40,000) for legal and due diligence expenses.


 




    	 	- 16 -	 



     


    

 


		9.	INDEMNIFICATION.



 


In consideration of
the Investor's execution and delivery of the Transaction Documents and acquiring the Purchase Shares hereunder and in addition
to all of the Company's other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold
harmless the Investor and all of its affiliates, stockholders, officers, directors, employees and any of the foregoing Person's
agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated
by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys'
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to: (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement
or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting
from the Company’s execution, delivery, performance of the Transaction Documents or any other certificate, instrument or
document contemplated hereby or thereby, (d) any violation of the Securities Act, the Exchange Act, state securities or “Blue
Sky” laws, or the rules and regulations of the Principal Market in connection with the transactions contemplated by the Transaction
Documents by the Company or any of its Subsidiaries, affiliates, officers, directors or employees, (e) any untrue statement or
alleged untrue statement of a material fact contained, or incorporated by reference, in the Registration Statement or any amendment
thereto or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a material
fact required to be stated therein or necessary to make the statements therein not misleading, or (f) any untrue statement or alleged
untrue statement of a material fact contained, or incorporated by reference, in the Prospectus, or any omission or alleged omission
to state therein, or in any document incorporated by reference therein, a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that
(I) the indemnity contained in clause (c) of this Section 9 shall not apply to any Indemnified Liabilities which directly and primarily
result from the fraud, gross negligence or willful misconduct of an Indemnitee, (II) the indemnity contained in clauses (d), (e)
and (f) of this Section 9 shall not apply to any Indemnified Liabilities to the extent, but only to the extent, arising out of
or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity
with written information furnished to the Company by or on behalf of the Investor expressly for use in any Prospectus Supplement,
if the Prospectus was timely made available by the Company to the Investor pursuant to Section 5(l), (III) the indemnity contained
in clauses (d), (e) and (f) of this Section 9 shall not inure to the benefit of the Investor to the extent such Indemnified Liabilities
are based on a failure of the Investor to deliver or to cause to be delivered the Prospectus made available by the Company, if
such Prospectus was timely made available by the Company pursuant to Section 5(l), and if delivery of the Prospectus would have
cured the defect giving rise to such Indemnified Liabilities, and (IV) the indemnity in this Section 9 shall not apply to amounts
paid in settlement of any claim if such settlement is effected without the prior written consent of the Company, which consent
shall not be unreasonably withheld, conditioned or delayed. To the extent that the foregoing undertaking by the Company may be
unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified
Liabilities which is permissible under applicable law. Payment under this indemnification shall be made within thirty (30) days
from the date Investor makes written request for it. If any action shall be brought against any Indemnitee in respect of which
indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company
shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any
Indemnitee shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i) the employment thereof
has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable written opinion of such separate
counsel furnished to the Company, a material conflict on any material issue between the position of the Company and the position
of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel.


 


		10.	EVENTS OF DEFAULT.



 


Unless waived in writing
by the Investor, an “Event of Default” shall be deemed to have occurred at any time as any of the following events
occurs:


 


(a) the effectiveness
of the Registration Statement registering the Purchase Shares lapses for any reason (including, without limitation, the issuance
of a stop order or similar order) or the Registration Statement or the Prospectus is unavailable for the sale by the Company to
the Investor (or the resale by the Investor) of any or all of the Purchase Shares to be issued to the Investor under the Transaction
Documents (including, without limitation, as a result of any failure of the Company to satisfy all of the requirements for the
use of a registration statement on Form S-3 pursuant to the Securities Act for the offering and sale of the Purchase Shares contemplated
by this Agreement), and such lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than
an aggregate of thirty (30) Business Days in any 365-day period;


 




    	 	- 17 -	 



     


    

 


(b) the suspension
of the Common Stock from trading or the failure of the Common Stock to be listed on the Principal Market for a period of one (1)
Business Day, provided that the Company may not direct the Investor to purchase any shares of Common Stock during any such suspension;


 


(c) the delisting
of the Common Stock from The NASDAQ Capital Market, provided, however, that the Common Stock is not immediately thereafter trading
on the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select Market or the NYSE MKT;


 


(d) the failure for
any reason by the Transfer Agent to issue Purchase Shares to the Investor within three (3) Business Days after the applicable Put
Closing Date which the Investor is entitled to receive such Purchase Shares;


 


(e) the Company breaches
any representation, warranty, covenant or other term or condition under any Transaction Document if such breach could have a Material
Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach continues for
a period of at least five (5) Business Days;


 


(f) if any Person
commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;


 


(g) if the Company,
pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case, (ii) consents to the entry of an order
for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially
all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally unable to pay its debts
as the same become due;


 


(h) a court of competent
jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case,
(ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders the liquidation of the
Company or any Subsidiary;


 


(i) if at any time
the Company is not eligible to transfer its Common Stock electronically as DWAC Shares; or


 


(j) if at any time
after the Commencement Date, the Exchange Cap is reached (to the extent the Exchange Cap is applicable pursuant to Section 2(e)
hereof).


 


In addition to any other rights and remedies
under applicable law and this Agreement, so long as an Event of Default has occurred and is continuing, or if any event which,
after notice and/or lapse of time, would become an Event of Default, has occurred and is continuing, or so long as the Closing
Market Price is below the Floor Price, the Company shall not deliver to the Investor any Put notice, and the Investor shall not
purchase any shares of Common Stock under this Agreement.


 


		11.	TERMINATION



 


This Agreement may
be terminated only as follows:


 


(a) If pursuant to
or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against
the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general
assignment for the benefit of its creditors (any of which would be an Event of Default as described in Sections 10(f), 10(g) and
10(h) hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth
below) without further action or notice by any Person.


 


(b) In the event that
the Commencement shall not have occurred on or before June 30, 2016, due to the failure to satisfy the conditions set forth in
Sections 7 and 8 above with respect to the Commencement, either the Company or the Investor shall have the option to terminate
this Agreement at the close of business on such date or thereafter without liability of any party to any other party (except as
set forth below); provided, however, that the right to terminate this Agreement under this Section 11(b) shall not be available
to any party if such party is then in breach of any covenant or agreement contained in this Agreement or any representation or
warranty of such party contained in this Agreement fails to be true and correct such that the conditions set forth in Section 7(c)
or Section 8(d), as applicable, could not then be satisfied.


 


(c) This Agreement
shall automatically terminate on the date that the Company sells and the Investor purchases the full number of Available Shares
as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to
any other party under this Agreement (except as set forth below).


 


(d) If for any reason
or for no reason the full number of Available Shares has not been purchased in accordance with Section 2 of this Agreement by the
Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of any
party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).


 




    	 	- 18 -	 



     


    

 


(e) by the mutual
written consent of the Company and the Purchaser.


 


Except as set forth in Sections 11(a) (in
respect of an Event of Default under Sections 10(f), 10(g) and 10(h)), any termination of this Agreement pursuant to this Section
11 shall be effected by written notice from one party hereto to the other, or the Investor to the Company, as the case may be,
setting forth the basis for the termination hereof. The representations and warranties and covenants of the Company and the Investor
contained in Sections 3, 4, 5, and 6 hereof, the indemnification provisions set forth in Section 9 hereof and the agreements and
covenants set forth in Sections 10, 11 and 12, shall survive the Commencement and any termination of this Agreement. No termination
of this Agreement shall (i) affect the Company's or the Investor's rights or obligations under this Agreement with respect to pending
Purchases and the Company and the Investor shall complete their respective obligations with respect to any pending Purchases under
this Agreement or (ii) be deemed to release the Company or the Investor from any liability for intentional misrepresentation or
willful breach of any of the Transaction Documents.


 


		12.	MISCELLANEOUS.



 


(a) Governing Law;
Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall govern all issues concerning the relative rights
of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation
of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of New York, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York, City of New York, County
of New York, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or
therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.


 


(b) Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature or signature delivered by e-mail in a “.pdf” format data file shall be considered due execution and shall
be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.


 


(c) Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.


 


(d) Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.


 


(e) Entire Agreement;
Amendment. This Agreement supersedes all other prior oral or written agreements between the Investor, the Company, their affiliates
and Persons acting on their behalf with respect to the subject matter hereof, and this Agreement, the other Transaction Documents
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein
and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation,
warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees that is has not relied on,
in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction
Documents. No provision of this Agreement may be amended other than by a written instrument signed by both parties hereto.


 


(f) Notices.
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile
or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses for such communications shall be:


 




    	 	- 19 -	 



     


    

 


If to the Company:


 


Immune Pharmaceuticals Inc.


430 East 29th Street, Suite
940


New York, NY 10016


Telephone: (646) 440-9310


Facsimile:


Email: daniel.teper@immunepharma.com


Attention:  Daniel G. Teper,
Chief Executive Officer


 


With a copy (which shall not
constitute notice or service of process) to:


 


Sichenzia Ross Friedman Ference


61 Broadway


New York, New York 10006


Telephone: (212) 930-9700


Facsimile: (212) 930-9725


Email: Rfriedman@srff.com


Attention: Richard Friedman,
Esq.


 


If to the Investor:


 


Regatta Select Healthcare, LLC


708 Third Avenue


New York, NY 10017


Telephone: (302)828-0020


Email: acc@regattaselect.com


Attention: L. Vigdor


 


With a copy (which shall not
constitute notice or service of process) to:


 


Grushko & Mittman, P.C.


515 Rockaway Avenue


Valley Stream, NY 11581


Telephone: (212) 697-9500


Facsimile:  (212) 697-3575


Email: barbaramittman@aol.com


Attention: Barbara R. Mittman,
Esq.


 


If to the Transfer
Agent:


 


VStock Transfer, LLC


18 Lafayette Place


Woodmere, NY 11598


Telephone:  (212) 828-8436


Facsimile:  (646) 536-3179


Email:


Attention:  


 


or at such other address and/or facsimile
number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other
party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient
of such notice, consent or other communication, (B) mechanically or electronically generated by the sender's facsimile machine
or email account containing the time, date, and recipient facsimile number or email address, as applicable, and an image of the
first page of such transmission or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence
of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with
clause (i), (ii) or (iii) above, respectively.


 




    	 	- 20 -	 



     


    

 


(g) Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Investor, including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.


 


(h) No Third Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.


 


(i) Publicity.
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the Investor
and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel
on, any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the Investor, its purchases
hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to
the issuance, filing or public disclosure thereof. The Investor must be provided with a final version of any such press release,
SEC filing or other public disclosure at least 24 hours prior to any release, filing or use by the Company thereof. The Company
agrees and acknowledges that its failure to fully comply with this provision constitutes a Material Adverse Effect.


 


(j) Further Assurances.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


(k) No Financial
Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Investor that it has not engaged any
financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Investor represents
and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with
the transactions contemplated hereby.


 


(l) No Strict Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party.


 


(m) Remedies, Other
Obligations, Breaches and Injunctive Relief. The Investor’s remedies provided in this Agreement, including, without limitation,
the Investor’s remedies provided in Section 9, shall be cumulative and in addition to all other remedies available to the
Investor under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief),
no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy
and nothing herein shall limit the Investor's right to pursue actual damages for any failure by the Company to comply with the
terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm
to the Investor and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event
of any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to seek an
injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
required.


 


(n) Enforcement
Costs. If: (i) this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced by the Investor
through any legal proceeding; (ii) an attorney is retained to represent the Investor in any bankruptcy, reorganization, receivership
or other proceedings affecting creditors' rights and involving a claim under this Agreement; or (iii) an attorney is retained to
represent the Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall pay to the
Investor, as incurred by the Investor, all reasonable costs and expenses including reasonable attorneys' fees incurred in connection
therewith, in addition to all other amounts due hereunder. If this Agreement is placed by the Company in the hands of an attorney
for enforcement or is enforced by the Company through any legal proceeding, then the Investor shall pay to the Company, as incurred
by the Company, all reasonable costs and expenses including reasonable attorneys' fees incurred in connection therewith, in addition
to all other amounts due hereunder.


 


(o) Waivers.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of
such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.


 




    	 	- 21 -	 



     


    

 


IN WITNESS WHEREOF,
the Investor and the Company have caused this Agreement to be duly executed as of the date first written above.


 


	 	THE COMPANY:	 
	 	 	 
	 	IMMUNE PHARMACEUTICALS INC.	 
	 	 	 	 
	 	By:	/s/ Daniel G. Teper	 
	 	Name:	Daniel G. Teper	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	 	THE INVESTOR:	 
	 	 	 
	 	REGATTA SELECT HEALTHCARE, LLC 	 
	 	 	 	 
	 	By:	/s/ L. Vigdor	 
	 	Name:	L. Vigdor	 
	 	Title:	Chief Financial Officer	 


 




    	 	- 22 -